$0.174
+0.018 (+10.06%)At close
AEON Comparative Benchmarking
In the context of the broader market, AEON competes directly with industry leaders such as CANF and NEUP. With a market capitalization of $12.44M, it holds a significant position in the sector. When comparing efficiency, AEON's gross margin of N/A stands against CANF's 100.00% and NEUP's 100.00%. Such benchmarking helps identify whether Aeon Biopharma Inc is trading at a premium or discount relative to its financial performance.
Aeon Biopharma Inc Financial Performance
The company's financials show a troubling trend with a net income of -37137000 USD in Q4 2025 and a current ratio of 0.54, indicating liquidity issues. The forward P/E ratio is 1.1577, suggesting potential undervaluation, but the negative gross profit figures raise concerns about profitability.
Financials
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.